Verastem’s VS-7375 oral therapy on FDA fast track for pancreatic cancer
The experimental oral medication VS-7375 has been granted fast track designation for advanced pancreatic cancer in the U.S. The Food and Drug Administration (FDA)…
Pancreatic cancer
Quemliclustat named orphan drug by FDA for pancreatic cancer
Quemliclustat has been granted an orphan drug designation in the U.S. as a potential treatment for pancreatic cancer. The U.S. Food and Drug Administration…
Daraxonrasib granted breakthrough designation for pancreatic cancer
Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with KRAS G12 mutations, has been…
Medicovestor’s pancreatic cancer therapy named FDA orphan drug
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADoBind MC001, an experimental treatment for pancreatic cancer that’s being developed…
Atebimetinib shows potential for advanced pancreatic cancer: Trial
Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression six months after starting treatment,…
Elraglusib nearly doubles 1-year survival rates in PDAC clinical trial
Actuate Therapeutics’ treatment candidate elraglusib significantly lowered the risk of death — about doubling one-year survival rates — among people with an advanced form…
Technique for PDAC may help increase effects of chemotherapy
Combining chemotherapy with focused ultrasound and microbubbles is safe and helps deliver chemotherapy drugs more effectively to tumors in people with inoperable pancreatic ductal adenocarcinoma…
PDAC antibody-drug conjugate EBC-129 wins FDA fast track status
U.S. regulators have granted fast track status to the Experimental Drug Development Centre’s (EDDC’s) candidate therapy for pancreatic ductal adenocarcinoma (PDAC), an aggressive form…
Geneseeq’s new blood test may detect early-stage pancreatic cancer
Geneseeq Technology is developing a blood test that uses cell-free DNA (cfDNA) and artificial intelligence (AI) to detect early-stage pancreatic ductal adenocarcinoma — the…
Adding elraglusib seen to improve survival in pancreatic cancer trial
Adding the experimental therapy elraglusib to standard chemotherapy led to statistically significant improvements in survival for people with metastatic pancreatic ductal adenocarcinoma (PDAC), a form…
